诺诚健华:调整募投项目结构并新增实施主体

公司公告
28 Mar

诺诚健华公告,公司拟调整首次公开发行A股募投项目的内部投资结构及部分项目实施主体,涉及新药研发、药物研发平台升级、营销网络建设及信息化建设项目。调整后,募投项目承诺投资总额27.788亿元保持不变。新增“ICP-B794”和“临床前分子”子项目,调减部分子项目投入,同时新增北京天实医药科技有限公司为营销网络建设项目实施主体。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10